Laura Vogel advises clients in the pharmaceutical and technology industries on intellectual property matters including litigation—particularly Hatch-Waxman litigation—patent prosecution and portfolio development; due diligence investigations; and freedom-to-operate, patentability, infringement, validity and inequitable conduct opinions. She has more than a decade of experience in pharmaceutical practice, and has been involved in more than 20 Abbreviated New Drug Application (ANDA) litigations as litigation counsel or co-counsel relating to all types of dosage forms: oral (tablets, capsules, ODTs, solutions), intravenous, intramuscular, ophthalmic formulations, transdermal patches, as well as abuse-resistant dosage forms. Her practice frequently involves Citizens Petition practice, as well as analysis of regulatory issues such as patent-based and FDA-granted exclusivities.

Laura also has significant experience representing clients in interferences before the United States Board of Patent Appeals and Interferences and now the U.S. Patent Trial and Appeal Board (PTAB), where she has served as lead counsel in multiple Inter Partes Reviews (IPRs). She prepares and prosecutes U.S. and foreign patent applications in the areas of biotechnology, pharmaceuticals, food sciences, molecular and cellular biology, recombinant DNA technology, therapeutic proteins, diagnostic assays, gene therapy, vaccines and tissue sealant technology.

Prior to joining Wolf Greenfield, Laura was a partner at Duane Morris LLP, where she represented pharmaceutical and biotech companies in opinion, litigation and prosecution matters, and played a key role in establishing the firm’s Hatch-Waxman (ANDA) litigation practice.